| ciprofloxacin (Q3939) / Bayer, Novartis |
NCT00961038: Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) |
|
|
| Completed | 1 | 19 | Europe | Ciprofloxacin (PulmoSphere, BAYQ3939), Placebo | Bayer, Novartis Pharmaceuticals | Pulmonary Disease, Chronic Obstructive | 03/10 | 03/10 | | |
NCT01072942: To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III) |
|
|
| Completed | 1 | 16 | Japan | Ciprofloxacin (Cipro InhaIe, BAYQ3939), Placebo | Bayer | Pulmonary Disease, Chronic Obstructive | 06/10 | 07/10 | | |
NCT01168895: Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder |
|
|
| Completed | 1 | 12 | Europe | Cipro Inhale (Ciprofloxacin, BAYQ3939) | Bayer | Infection, Pulmonary Disease, Chronic Obstructive | 09/10 | 09/10 | | |
